In the intricate world of pharmaceutical manufacturing, the quality of intermediates directly dictates the efficacy and safety of the final Active Pharmaceutical Ingredient (API). For those involved in the synthesis of Dronedarone, a critical medication for managing cardiac arrhythmias, understanding the procurement of key intermediates is paramount. One such crucial compound is (2-Butyl-5-nitrobenzofuran-3-yl)(4-hydroxyphenyl)methanone, identified by its CAS number 141645-16-1.

This pale yellow solid plays a pivotal role in the complex synthetic pathways leading to Dronedarone and its hydrochloride salt. Its chemical structure, featuring a benzofuran core with specific functional groups, makes it an indispensable building block for medicinal chemists and product formulators. Procurement managers actively seeking a reliable supplier for this intermediate will often prioritize purity, consistency, and supply chain stability – factors that directly impact production timelines and costs.

When sourcing (2-Butyl-5-nitrobenzofuran-3-yl)(4-hydroxyphenyl)methanone, key specifications to scrutinize include its purity level, typically requiring ≥99%, and its impurity profile, with stringent limits like ≤0.2%. Moisture content, usually expected to be ≤0.5%, is another critical parameter to ensure product integrity during storage and use. Manufacturers specializing in pharmaceutical intermediates, particularly those based in China, often provide detailed Certificates of Analysis (CoA) to verify these specifications.

For businesses looking to buy this essential Dronedarone intermediate, engaging with established manufacturers and suppliers is the most strategic approach. Companies that offer comprehensive product documentation, competitive pricing, and flexible packaging solutions, such as 25kg cardboard drums or custom options, stand out. These suppliers understand the demands of global pharmaceutical supply chains and are equipped to handle both research and development quantities and large-scale production orders. The ability to obtain a timely quote and secure consistent supply from a trusted manufacturer is essential for uninterrupted production of vital cardiovascular medications.